India
oi-Deepika S
New Delhi, Jan 02: Indian Council of Medical Research (ICMR) director Balram Bhargava on Sunday said that the Bharat Biotech vaccine may have some advantages over other vaccines on the new mutant strain first detected in the UK.
His observations came amid politicians from several opposition parties raising doubts over the efficacy of Covaxin, that is still in Phase 3 trials.
Bhargava also said Covaxin is based on an inactivated whole virus, having potential to target mutated coronavirus strains including the UK variant, which was a major ground for giving it a conditional nod.
He, however, said no clear data regarding the efficacy of the vaccine is available so far.
“We don’t know for how long a vaccine is going to be effective, we don’t know how much of the population…